GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878
REGD. OFFICE &FACTORY: 69/C GIDC INDUSTRIAL ESTATE,
VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA
TEL: 0260-2430027 / 2400639
E-mail:hrm@gtbl.in.net

GTBL/BSE/NSE/2026-27/46

7th August, 2026

Corporate Relationship Department
BSE Limited
Floor 25, Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code – 506879

Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400051
Symbol: GUJTHEM

Dear Sir / Madam,

Sub: Investor Presentation

In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), we submit herewith the Investors' Presentation of the Gujarat Themis Biosyn Limited ('the Company') for the quarter ended 30th June, 2026.

Further, a copy of the same is also available on the website of the Company at http://www.gtbl.in

Kindly take the same on record and acknowledge receipt of the same.

Thanking you,

Yours faithfully,

For **Gujarat Themis Biosyn Limited**

VINEET GANESH GAWANKAR
Digitally signed by VINEET GANESH GAWANKAR
Date: 2026.08.07 16:58:40 +05'30'

Vineet Gawankar
Company Secretary and Compliance Officer

Encl.: a/a

Gujarat Themis Biosyn Limited

Investor Presentation

Q1 FY2026-27

Disclaimer

This presentation has been prepared by ***Gujarat Themis Biosyn Limited (the "Company" or "GTBL")*** *solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.*

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.

Management Comment

Commenting on the result, **Dr. Sachin Patel, Managing Director,** said:

"We are happy to share that the company has begun the new financial year on a strong note, continuing on our growth momentum. We witnessed healthy levels of sales volumes, reflecting a stable demand scenario in the market. This, in turn, helped boost topline, and trickled through to our margins, which showed improvement year-on-year.

As you are aware, we made significant strides in our inorganic expansion initiatives recently. Our acquisition of Sanofi's brands is expected to give us access to new distribution networks across key overseas markets. And the acquisition of MicroBiopharm in Japan complements and strengthens our manufacturing capabilities, technological know-how, as well as product offerings. These moves not only widen our therapy areas, but also broaden our geographical reach, and are major milestones in our evolution as a global CDMO player.

Coming to our capex in India, while the new R&D and API units are up and running, development of our new fermentation facility is also complete. Our hybrid power plant in Gujarat is well underway, which will be used for captive consumption. This is expected to reduce our power costs and dependence on the grid, as well as lower our carbon footprint, supporting environmental sustainability.

In Q1 FY27, our top line grew 22.1% year-on-year to Rs. 43.8 crores; EBITDA increased 49.4% to Rs. 20.8 crores, while PAT improved 22.1% to Rs. 11.1 crores. Economies of scale due to higher volumes helped enhance EBITDA margin. The EPS for the quarter is Rs. 1.02."

Acquisition of MicroBiopharm Japan Co., Ltd.

DEAL SNAPSHOT

JPY 21.5 Bn

Deal Value | ~INR 1,300 Crore

100%

Stake Acquired | Via wholly owned SPV in Japan

T Capital Partners

Seller | Japan-based PE Fund

Q2 FY2027

Expected Close | Subject to regulatory approvals

JPY 9.5 Bn

Revenue (FY26E) | ~INR 575 Crore

Wider Product Portfolio & Therapeutic Coverage

Expanded portfolio of products & therapy areas

Broadens GTBL's API and intermediates portfolio across oncology, immunosuppressants, and peptides — enhancing product depth and revenue diversification

Technology

Novel Biotech Platforms

Proprietary P450 enzyme library, Plasmid DNA, ADC Conjugation and Strain & Process Optimization technologies

Customers

Big Pharma Relationships

Serving Top 6 global pharma customers for 20+ years; 40% revenues from outside Japan across Asia, Europe & North America

Strategic Fit

Fermentation CDMO Platform

Accelerates GTBL's transition to a globally integrated, fermentation-based CDMO with expanded API, biologics & precision fermentation capabilities

Creates a scaled, innovation-led end-to-end pharma platform — combining expanded therapeutic coverage, advanced technologies & global customer access

Agreement with Sanofi to Acquire Select Product Portfolio

DEAL SNAPSHOT

~EUR 158 Mn

Deal Value | Funded via debt & equity mix

~EUR 62 Mn

Portfolio Revenue | FY 2025 actuals

13 Brands

Brands Acquired | Established global brands

55+ Countries

Global Reach | Europe, MEA & other markets

~70%

Retail Channel | Retail contribution to revenue

Portfolio

TB & Anti-Infective Focus

13 established brands across tuberculosis & anti-infectives; key molecules include Levofloxacin, Rifampicin & Rifapentine — WHO Essential & EU Critical Medicines

Structure

Asset-Light Model

Structured as asset acquisition (Brands + MAs + Dossiers + Inventory) — no manufacturing capex or employee transfer; immediate access to regulated markets

Integration

Value Chain Integration

Builds Intermediates → API → Finished Dosage integration, leveraging GTBL's fermentation strength and driving forward integration across the value chain

Financial Impact

EPS Accretive + Margin Upside

Expected to be EPS accretive with healthy gross margins; additional upside from API integration, cost optimization & dormant MA reactivation across 55+ countries

Asset-light acquisition delivers immediate global market access, established brand equity & long-term margin expansion potential

Quarterly Financial Highlights

Revenue (Rs. Cr)



EBITDA* (Rs. Cr) / Margin (%)



PAT (Rs. Cr) / Margin (%)



*EBITDA excluding other income

Quarterly P&L Highlights

Rs. Cr.	Q1 FY27	Q1 FY26	YoY%	Q4 FY26
Income from Operations	43.79	35.87		44.23
Other Operating Income	0.00	0.00		0.00
Total Income from Operations	**43.79**	**35.87**	**22.07%**	**44.23**
Cost of Materials Consumed	7.73	6.83		10.05
Changes In Inventory	(3.91)	(0.20)		(6.50)
Employee Cost	4.72	3.11		3.79
Other Cost	14.46	12.21		17.52
Total Expenditure	**23.00**	**21.95**	**4.76%**	**24.87**
EBITDA	**20.79**	**13.92**	**49.37%**	**19.36**
EBITDA Margin %	**47.48%**	**38.81%**	**867 bps**	**43.77%**
Other Income	0.13	0.27		0.92
Depreciation	3.97	2.03		4.04
Interest	1.79	0.04		1.91
Profit Before Tax	**15.17**	**12.12**	**25.13%**	**14.34**
Tax	4.10	3.06		3.45
Profit After Tax	**11.07**	**9.06**	**22.13%**	**10.89**
PAT Margin %	**25.27%**	**25.26%**	**1 bps**	**24.62%**
EPS (in Rs.)	1.02	0.83	22.89%	1.00

- Healthy growth in top line driven by optimized production and increase in sales volumes
- Higher volumes helped offset increase in employee & other costs, boosting EBITDA margins

Annual Financial Highlights

Rs. Cr.	FY26	FY25	YoY%
Income from Operations	165.82	150.80	
Other Operating Income	0.00	0.00	
Total Income from Operations	**165.82**	**150.80**	**9.96%**
Cost of Materials Consumed	30.43	25.78	
Changes In Inventory	(9.03)	(1.27)	
Employee Cost	16.51	12.64	
Other Cost	52.38	44.81	
Total Expenditure	**90.29**	**81.96**	
EBITDA	**75.53**	**68.84**	**9.71%**
EBITDA Margin %	**45.55%**	**45.65%**	**(10 bps)**
Other Income	2.43	2.43	
Depreciation	12.92	5.37	
Interest	2.95	0.36	
Profit Before Tax	**62.09**	**65.54**	**(5.26%)**
Tax	15.41	16.77	
Profit After Tax	**46.68**	**48.77**	**(4.29%)**
PAT Margin %	**28.15%**	**32.34%**	**(419 bps)**
EPS in Rs.	4.28	4.48	(4.46%)

Annual Financial Highlights







Balance Sheet Highlights – As on 31st March 2026

Rs. Cr. Total Equity & Liabilities	As on 31st Mar, 2025	As on 31st Mar, 2026
Shareholders Funds	**248.38**	**287.77**
Share Capital	10.90	10.90
R&S	237.49	276.87
Non Current Liabilities	**32.37**	**136.51**
Financial Liabilities		
Borrowings	29.64	128.06
Lease Liabilities	0.00	0.65
Provisions	0.77	1.21
Deferred Tax Liabilities (Net)	1.96	6.59
Current Liabilities	**20.56**	**79.15**
Financial Liabilities		
Short term borrowing	0.25	31.80
Lease Liabilities	0.58	1.30
Trade Payables	14.65	36.65
Other Trade Payables		
Other financial liabilities	4.28	5.89
Provisions	0.28	0.31
Other Current Liabilities	0.51	3.05
Current Tax Liability (Net)	0.00	0.14
Total Equity & Liabilities	**301.31**	**503.43**

Rs. Cr. Total Assets	As on 31st Mar, 2025	As on 31st Mar, 2026
Non Current Assets	**249.34**	**414.64**
Property Plant & Equipment	40.58	286.92
Capital work in progress	184.41	121.13
Right of use Assets	0.55	1.96
Financial Assets – Loans	0.75	0.75
Other Financial Assets	1.62	0.93
Other Non Current Assets	21.27	2.85
Other Intangible Assets	0.16	0.10
Current Assets	**51.97**	**88.78**
Inventories	5.05	15.42
Financial assets		
Investments	0.00	0.00
Trade receivables	31.24	60.92
Cash & Cash equivalents	11.69	3.12
Bank balance other than above	0.85	2.97
Short Term Loans	0.00	0.01
Other financial assets	0.99	0.33
Other Current Assets	2.14	6.02
Total Assets	**301.31**	**503.43**

Key Balance Sheet Ratios







Company has been investing in Capex over last two years, leading to higher Capital Employed & Asset base

******RoE = Net Profit/Net Worth | **RoA = Net Profit/Average Total Assets / *RoCE = EBIT/(Shareholders Fund + Total Debt-non current investments)***

Among India's few Fermentation based Intermediate manufacturer

GTBL among one of India's few fermentation-based manufacturers in pharmaceutical field

01

- Incorporated in 1981 as joint sector Company with GIIC Ltd. and Chemosyn (P) Ltd.
- India's First Company to start commercial production of Antituberculosis drug Rifampicin

Product Portfolio – strong & growing

02

- Rifamycins – Treatment of Tuberculosis and digestive tract infections
- First to start commercial production of Rifampicin using Fermentation process

Focus on R&D

03

- Company is establishing state of art R&D facilities
- Focus now is to develop new products in line with business strategy

State of Art Manufacturing Facility

04

- Plant in Vapi (Gujarat)
- Approx. 200 Employees engaged at plant site

Strong Collaborations

05

- Technical and commercial collaborations to facilitate adoption of best technologies and processes
- Inorganic expansion initiatives

Strong Financial Performance

06

- Strong cash flows
- Healthy margins
- Comfortable debt levels

Strong & Niche Product Portfolio – Growing at a fast pace

Current Product Portfolio

Rifamycin S

- An intermediate for manufacturing drug Rifampicin (Anti biotic used for treatment of several types of bacterial infections, including tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease)

Rifamycin O

- An intermediate for manufacturing drug Rifaximin (Antibiotic used for treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy)

Capacities of up to 990 KL

Expansion Strategy to Spur Growth

Capex

Research & Development

- New Product Development
- R&D Unit Commissioned, as per International Standards
- R&D Initiatives towards developing new Intermediate molecules

Forward Integration

- Ventured into API production as part of forward integration strategy
- Started commercial operations at new API unit
- Leverage expertise in Rifa-based products, amongst others, to develop range of APIs

Fermentation

- Expanding fermentation capacity
- Additional capacity to be used for newly developed products
- Expand Product portfolio & target domestic as well as export markets

State of Art Manufacturing Facilities at Vapi

Among very few companies in India with fermentation capabilities for Intermediates

Environment Friendly & Sustainable Process Using Aerobic Bacteria for Fermentation

Our Way Ahead

New Product Development & Forward Integration

- In process of identifying new products which have good domestic & export potential
- Company strategizing to move up the value chain through forward integration into API – recently began commercial operations at new API facility

New Infrastructure Development

- New infrastructure would be compliant with international regulatory norms
- Focusing on enhancing fermentation capacities

Focus on Establishing R&D Centre

- New R&D lab to take care of technology development for new products and for examining whether existing products can be used for more applications

Inorganic Expansion & Geographical Diversification

- Explore inorganic growth opportunities globally
- Expand geographical reach as well as therapy areas

Enhance Capacity to meet future growth

- Fermentation capacity expansion at current location
- Open to both Organic and Inorganic opportunities for growth in Specialty Chemical space

Hybrid Renewable Power Project

Strategic ESG & Cost Optimization Initiative

- Advancing the Company's ESG roadmap through increased adoption of renewable energy for captive consumption, thus lowering carbon footprint
- Hybrid wind–solar configuration designed to deliver more consistent & reliable green power across seasons
- Reduces dependence on grid electricity, enhancing energy security for manufacturing
- Provides long-term visibility & optimization of power costs, supporting margin stability
- Reinforces sustainability-led growth while aligning operations with evolving regulatory expectations



Capacity
Wind + Solar Hybrid
~ 18 MW

Energy Strategy
Captive consumption
Reduced grid reliance

Strategic Benefits
Lower power costs
Improved ESG Profile

Thank You

For further information, please contact:

Company :	Investor Relations Advisors :
Gujarat Themis Biosyn Limited	**Adfactors PR Pvt. Ltd.**
Mr. Krupesh Patel, CFO krupesh.patel@themismedicare.com	Mr. Rahul Trivedi Mr. Sumit Kinikar rahul.trivedi@adfactorspr.com sumit.kinikar@adfactorspr.com
www.gtbl.in	www.adfactorspr.com